EHNA HCl |
Katalog-Nr.GB40191 |
EHNA (51350-19-7) inhibits phosphodiesterase 2 (PDE2) (IC50 = 0.8 - 5.5 µM in a variety of tissues and species) over PDE1, PDE3, or PDE4 (IC50 values > 100 µM). It also inhibits adenosine deaminase (ADA), IC50 = 1.2 and 1.5 µM in human RBCs and astrocytoma cells, respectively, which may be responsible for its ability to induce apoptosis in malignant pleural mesothelioma cell lines. Because it blocks breakdown of adenosine to inosine and hypoxanthine, EHNA prevents formation of free radical substrates, protecting against cardiac reperfusion-mediated injury. It inhibits differentiation and maintains expression of pluripotency markers in hESCs, but not through inhibition of PDEs or ADA.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 51350-19-7
Sample solution is provided at 25 µL, 10mM.
EHNA (51350-19-7) inhibits phosphodiesterase 2 (PDE2) (IC50 = 0.8 - 5.5 µM in a variety of tissues and species) over PDE1, PDE3, or PDE4 (IC50 values > 100 µM). It also inhibits adenosine deaminase (ADA), IC50 = 1.2 and 1.5 µM in human RBCs and astrocytoma cells, respectively, which may be responsible for its ability to induce apoptosis in malignant pleural mesothelioma cell lines. Because it blocks breakdown of adenosine to inosine and hypoxanthine, EHNA prevents formation of free radical substrates, protecting against cardiac reperfusion-mediated injury. It inhibits differentiation and maintains expression of pluripotency markers in hESCs, but not through inhibition of PDEs or ADA.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *